Panzyga (Human Normal Immunoglobulin)

Panzyga is an immunoglobulin therapy that acts on disorders of the immune system requiring antibody replacement.

• Primary immunodeficiency diseases: provides functional antibodies to reduce infection risk.
• Chronic immune thrombocytopenia (ITP): helps raise platelet counts in refractory cases.
• Multifactorial immune‑mediated neuropathies: may improve neurological function and pain relief.
• Secondary hypogammaglobulinemia after hematopoietic stem cell transplantation: supports immune reconstitution.
• Certain autoimmune hemolytic anemias: contributes to hemolysis control.
• Off‑label use in some viral infections where antibody support is beneficial.

• Panzyga supplies pooled human IgG antibodies that bind a broad spectrum of antigens, neutralising pathogens, modulating complement activation and interacting with Fc receptors on immune cells. This restores humoral immunity, down‑regulates inflammatory pathways and provides immunomodulatory effects that help rebalance dysregulated immune responses.

Adverse reactions to Panzyga are reported across a range of frequencies.

Common Side Effects

• Headache: mild to moderate intensity.
• Fever or chills: transient during or after infusion.
• Nausea or vomiting: generally mild.
• Fatigue or malaise: common post‑infusion.
• Injection site erythema or swelling: localized reaction.
• Hypertension: temporary rise in blood pressure.

Serious or Rare Side Effects

• Anaphylaxis or severe hypersensitivity: immediate medical attention required.
• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Acute renal failure: especially with rapid infusion rates.
• Aseptic meningitis: rare neurologic complication.
• Hemolytic transfusion reactions: immune‑mediated red cell destruction.
• Severe hemolysis or hemolytic anemia: requires urgent care.

When using Panzyga, clinicians should consider several safety measures.

• Infusion rate: adjust to patient tolerance to minimise reactions.
• Pre‑medication: antihistamines or steroids may be given to reduce hypersensitivity.
• Renal function: monitor creatinine and urine output, especially in high‑risk patients.
• Cardiovascular status: observe for hypertension or fluid overload.
• Thrombotic risk: assess history of clotting disorders before therapy.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other agents, influencing safety or efficacy.

Major Interactions (Avoid)

• Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk.
• High‑dose aspirin or NSAIDs: may raise bleeding risk when combined with immunoglobulin‑induced platelet changes.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may augment immunosuppressive effects, requiring dose adjustment.
• Anticoagulants (e.g., warfarin): monitor INR closely as immunoglobulin can affect coagulation parameters.
• Diuretics: fluid shifts during infusion may potentiate electrolyte disturbances.
• ACE inhibitors: watch for additive hypertension.
• Rituximab: combined immunosuppression may increase infection susceptibility.